A carregar...
Efficacy and Safety of [(225)Ac]Ac-PSMA-617 Augmented [(177)Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis
The use of (225)Ac in prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT), either as monotherapy or in combination with (177)Lu, is a promising therapy approach in patients with metastatic castration-resistant prostate carcinoma (mCRPC). In this study, we report the efficacy...
Na minha lista:
| Publicado no: | Pharmaceutics |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8156464/ https://ncbi.nlm.nih.gov/pubmed/34069003 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/pharmaceutics13050722 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|